HTG Molecular Diagnostics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of HTG Molecular Diagnostics generated cash of -$18,407,791, which is less than the previous year. Cash used in financing activities reached the amount of $8,604,820 last year. Net change in cash is therefore $2,610,907.
Cash Flow
| 2013 | -11.82M | -777.76K | 7.10M |
|---|---|---|---|
| 2014 | -12.99M | -857.67K | 15.65M |
| 2015 | -19.24M | -32.18M | 51.10M |
| 2016 | -22.23M | 24.42M | 2.02M |
| 2017 | -16.57M | 3.27M | 15.75M |
| 2018 | -13.17M | -23.22M | 38.12M |
| 2019 | -16.69M | -3.50M | 19.39M |
| 2020 | -16.29M | 18.73M | 9.04M |
| 2021 | -16.50M | -6.66M | 10.39M |
| 2022 | -18.40M | 12.42M | 8.60M |
HTGM Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 9.59M | 22.39M | 10.88M | 11.70M | 9.96M | 7.50M | 3.29M | 3.61M | 1.81M | 7.31M |
Operating activities | ||||||||||
Net income | -21.59M | -17.14M | -20.87M | -19.29M | -16.45M | -18.96M | -26.03M | -21.39M | -13.95M | -11.76M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 587.13K | 721.24K | 1.34M | 1.73M | 1.46M | 1.24M | 1.47M | 662.56K | 496.59K | 315.08K |
Stock-based compensation expense | 814.50K | 1.37M | 1.81M | 1.22M | 0 | 0 | 0 | 0 | 0 | 88.09K |
| Deferred income tax benefit | 814.50K | 1.37M | 1.81M | 1.22M | 0 | 0 | 0 | 0 | 0 | 88.09K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 670.77K | -805.73K | 1.57M | 1.84M | 1.33M | -4.97M | -661.19K | 40.02K | -312.34K | -456.43K |
Inventories | 140.82K | -1.36M | -256.94K | -116.78K | -171.90K | 77.17K | -33.21K | -746.24K | -746.98K | -621.05K |
Accounts payable | -525.17K | 453.33K | -23.80K | -155.97K | -150.17K | 1.22M | 10.07K | -312.27K | 198.19K | 146.89K |
Cash generated by operating activities | -18.40M | -16.50M | -16.29M | -16.69M | -13.17M | -16.57M | -22.23M | -19.24M | -12.99M | -11.82M |
Investing activities | ||||||||||
Purchases Of Investments | -7.61M | -18.62M | -12.46M | -34.60M | -53.97M | 0 | -3.38M | -38.34M | 0 | 0 |
Investments In Property Plant And Equipment | -23.04K | -644.38K | -453.55K | -1.10M | -949.51K | -1.02M | -1.94M | -1.33M | -857.67K | -777.76K |
Acquisitions Net | 0 | -25.01B | -72.50M | -325.66B | -412.43B | 0 | 172.04M | 0 | 0 | 0 |
Cash generated by investing activities | 12.42M | -6.66M | 18.73M | -3.50M | -23.22M | 3.27M | 24.42M | -32.18M | -857.67K | -777.76K |
Financing activities | ||||||||||
Common Stock Issued | 1.40M | 10.66M | 7.54M | 20.75M | 38.28M | 20.17M | 2M | 47.65M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.92K | 0 | 0 |
Repayments of term debt | 0 | -766.43K | -3.61M | 0 | -6.02M | 0 | -4.57M | 0 | -771.93K | 0 |
Cash used in financing activities | 8.60M | 10.39M | 9.04M | 19.39M | 38.12M | 15.75M | 2.02M | 51.10M | 15.65M | 7.10M |
Net Change In Cash | 2.61M | -12.79M | 11.50M | -812.85K | 1.73M | 2.46M | 4.21M | -319.40K | 1.79M | -5.50M |
Cash at end of period | 12.21M | 9.59M | 22.39M | 10.88M | 11.70M | 9.96M | 7.50M | 3.29M | 3.61M | 1.81M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |